Medico Remedies Ltd Upgraded to Hold as Technicals Improve and Financials Strengthen

Technical Trends Show Signs of Stabilisation

The primary catalyst for the upgrade stems from a shift in the technical grade from bearish to mildly bearish. While the weekly and monthly MACD indicators remain bearish, other technical signals suggest a tempering of downward momentum. The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, indicating a potential pause in selling pressure.

Bollinger Bands on weekly and monthly timeframes have moved to mildly bearish, reflecting reduced volatility and a possible consolidation phase. Daily moving averages also align with this mildly bearish stance, suggesting that the stock price is stabilising after recent declines.

Notably, the Dow Theory weekly indicator has turned mildly bullish, and the On-Balance Volume (OBV) weekly reading supports this with a mildly bullish trend, hinting at accumulation by investors. However, the KST oscillator remains bearish on both weekly and monthly scales, indicating caution is still warranted.

These mixed technical signals have collectively contributed to a more balanced outlook, prompting the upgrade to Hold from a previously negative stance.

Valuation Remains Fair with Discount to Peers

Medico Remedies is currently trading at ₹42.70, up 4.55% on the day, with a 52-week range between ₹35.00 and ₹62.00. Despite a recent one-year return of -26.78%, the stock’s valuation metrics suggest it remains attractively priced relative to its sector peers. The company’s Enterprise Value to Capital Employed ratio stands at a reasonable 4.7, reflecting fair valuation given its operational scale.

The Price/Earnings to Growth (PEG) ratio is 1, indicating that the stock’s price is in line with its earnings growth prospects. This valuation is supported by a Return on Capital Employed (ROCE) of 15.8%, which is respectable within the pharmaceuticals industry and signals efficient capital utilisation.

Compared to the broader market, Medico Remedies has underperformed the Sensex and BSE500 indices over the past one and three years, but its discounted valuation relative to peers offers a potential entry point for investors seeking value in the micro-cap segment.

Financial Trends Highlight Robust Profit Growth and Debt Management

Medico Remedies has demonstrated positive financial performance in the third quarter of FY25-26, with consistent profit growth over the last four quarters. The company reported a Profit After Tax (PAT) of ₹5.44 crores for the latest six months, reflecting a robust growth rate of 30.46%. This is complemented by a strong Profit Before Tax excluding Other Income (PBT less OI) of ₹3.15 crores for the quarter, which surged by 52.17% year-on-year.

Return on Capital Employed (ROCE) has improved significantly, reaching 20.65% in the half-year period, underscoring efficient utilisation of capital resources. The company’s debt servicing capability remains strong, with a low Debt to EBITDA ratio of 0.82 times, indicating manageable leverage and financial stability.

These financial metrics underpin the company’s ability to sustain growth and maintain operational efficiency, justifying the Hold rating despite recent share price underperformance.

Quality Assessment Reflects High Management Efficiency

Medico Remedies’ quality grade has been bolstered by its high management efficiency, as evidenced by the consistent improvement in key profitability ratios. The company’s ROCE of 15.04% is a testament to its effective capital allocation and operational discipline. Promoter shareholding remains majority, providing stability and alignment of interests with shareholders.

However, the company’s long-term stock performance remains below par, with a three-year return of -47.78% compared to a 31.62% gain in the Sensex. This underperformance highlights the need for cautious optimism, as the company works to translate its improving fundamentals into sustained market gains.

Market Performance and Outlook

Despite the recent upgrade, investors should note that Medico Remedies has delivered mixed returns over various time horizons. The stock outperformed the Sensex over the past week and month, generating returns of 10.54% and 12.16% respectively, compared to Sensex gains of 0.52% and 5.34%. However, year-to-date and one-year returns remain negative at -15.55% and -26.78%, underperforming the Sensex’s -7.87% and -1.36% respectively.

Longer-term performance is also subdued, with a three-year return of -47.78% against a 31.62% rise in the Sensex. Nevertheless, the stock’s five-year return of 682.77% significantly outpaces the Sensex’s 63.30%, reflecting strong historical growth that has recently moderated.

Given these mixed signals, the Hold rating reflects a balanced view that acknowledges improving fundamentals and technicals while recognising the need for further evidence of sustained market recovery.

Conclusion

The upgrade of Medico Remedies Ltd from Sell to Hold is driven by a combination of improved technical indicators, fair valuation metrics, positive financial trends, and high management efficiency. While the stock’s recent price performance has been disappointing relative to benchmarks, the company’s strong profit growth, manageable debt levels, and stabilising technical signals provide a foundation for cautious optimism.

Investors should monitor upcoming quarterly results and market developments closely to assess whether the company can convert these improvements into sustained share price appreciation. For now, the Hold rating suggests that Medico Remedies is a stock to watch, offering potential value but requiring patience amid ongoing sector and market volatility.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →